Newsmeme!
Discover News you didn't know existed
Idiopathic
News
S*BIO Advances JAK2 Inhibitor SB1518 Into Phase 1/2 Clinical Trial In Australia For The Treatment Of Chronic ...
Published December 2, 2008, 3:11 am, Medical News Today
S*BIO Pte Ltd announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients.
initiation medical centers phase 1 pte ltd
Tags
No tags found at this time. Be the first to tag this news item, learn more.
Imagery
Related Idiopathic Stories
From Various News Sources
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in ... - Yahoo Finance
SINGAPORE, Dec. 2 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic ...
Related Social Bookmarks
None found at this time.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |